Ajay K. Nooka, MD, MPH, FACP

One star
One star
One star
One star
One half star

Rating: 4.9 out of 5 (421 ratings)

Role

Hematology Oncology
Specialty

Myeloma and Plasma Cell Disorders
Research Program

Cancer Prevention and Control
Practicing Since

2011

Request Appointment

Background

Ajay Kumar Nooka, MD, MPH, FACP, is a board certified hematologist specializing in the treatment of patients with multiple myeloma and plasma cell disorders.

Dr. Nooka serves as associate director of clinical research for Winship Cancer Institute of Emory University. In this role, he provides strategic oversight for all clinical research conducted at Winship, with a focus on supporting high-quality, safe and ethical research and ensuring that patients have equitable access to Winship’s innovative clinical trials. He also serves as scientific director of the Winship Data and Technology Applications Shared Resource at Winship Cancer Institute of Emory University and as director of the Myeloma Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine.

Dr. Nooka is a clinical member of the Cancer Prevention and Control Research Program at Winship Cancer Institute of Emory University. He serves on the steering committee of the Multiple Myeloma Research Consortium.

Titles & Roles

Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine
Associate Director of Clinical Research

Winship Cancer Institute of Emory University
Director, Myeloma Program, Department of Hematology and Medical Oncology

Emory University School of Medicine
Scientific Director, Winship Data and Technology Applications Shared Resource

Winship Cancer Institute of Emory University

Education & Training

Education

Fellowship, Hematology & Oncology, 2011
Winship Cancer Institute
Residency, Internal Medicine, 2008
Canton Medical Education Foundation
Medical Education, , 2000
NTR University of Health Sciences/Andhra Medical College

Board Certifications

Medical Oncology
American Board of Internal Medicine, 2011
Hematology
American Board of Internal Medicine, 2011
Internal Medicine
American Board of Internal Medicine, 2008

Research

Dr. Nooka's research interests include integrating genomic and clinical data on a uniform platform; interpreting data in a meaningful way to risk-stratify myeloma; and evaluating newer myeloma therapeutic strategies aimed at prolonging survival in myeloma patients. He also focuses on cancer epidemiology.

View Current Clinical Trials


A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma Phase I Conditions Multiple Myeloma Location Winship Cancer Institute
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma Phase II Conditions Plasma Cell Myeloma Location Winship Cancer Institute
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia Phase II Conditions Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Central Nervous System Lymphoma Location Winship Cancer Institute
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb Phase II Conditions Multiple Myeloma Location Emory Saint Joseph's Hospital, Winship Cancer Institute
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma Phase I/II Conditions Hematological Malignancies Location Winship Cancer Institute
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) Phase I/II Conditions Multiple Myeloma Location Emory University Hospital Midtown, Winship Cancer Institute
Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma Phase I Conditions Multiple Myeloma in Relapse Location Emory University Hospital Midtown, Winship Cancer Institute
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) Phase III Conditions Multiple Myeloma Location Emory University Hospital Midtown, Winship Cancer Institute

Publications

Dr. Nooka serves on the editorial board for The American Journal of Clinical Oncology, Journal of Hematological Malignancies, Lymphoma and Chronic Lymphocytic Leukemias, and serves as section editor of hematologic malignancies for Cancer. He is an ad hoc journal reviewer for Annals of Oncology, Oncology, Leukemia Research, Bone Marrow Transplantation, Biology of Blood and Marrow Transplantation, European Journal of Cancer, Current Oncology, Indian Journal of Medical Research and International Journal of Hematology.

Title/Journal	Authors	Publication Date
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. The Lancet. Oncology	P Rodriguez-Otero, S Usmani, AD Cohen, NWCJ van de Donk, X Leleu, JG Pérez-Larraya, S Manier, AK Nooka, MV Mateos, H Einsele, M Minnema, M Cavo, BA Derman, N Puig, F Gay, PJ Ho, WJ Chng, E Kastritis, G Gahrton, K Weisel, C Nagarajan, F Schjesvold, J Mikhael, L Costa, NS Raje, E Zamagni, R Hájek, N Weinhold, K Yong, JC Ye, S Sidhana, G Merlini, T Martin, Y Lin, A Chari, R Popat, JL Kaufman	01/05/2024
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study. British journal of haematology	AK Nooka, JL Kaufman, C Rodriguez, A Jakubowiak, Y Efebera, B Reeves, TM Wildes, SA Holstein, LD Anderson, A Badros, L Shune, A Chari, H Pei, A Cortoos, S Patel, TS Lin, PM Voorhees, SZ Usmani, PG Richardson	19/03/2024
Acute Pulmonary Injury in Hematology Patients Supported with Pathogen Reduced and Conventional Platelet Components. Blood advances	AP Wheeler, EL Snyder, MA Refaai, CS Cohn, J Poisson, MJ Fontaine, M Sehl, AK Nooka, L Uhl, PC Spinella, M Fenelus, DK Liles, T Coyle, J Becker, MR Jeng, EA Gehrie, BR Spencer, PP Young, AD Johnson, J O'Brien, GJ Schiller, JD Roback, E Malynn, R Jackups, S Avecilla, K Liu, S Bentow, J Varrone, RJ Benjamin, L Corash	06/03/2024
Shrinking the divide: improving myeloma CART access. Blood advances	AK Nooka, MA Hartley-Brown, KC Anderson, S Lonial	09/01/2024
Glücksklee, the Quad, and High-Risk Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	AK Nooka, JL Kaufman, S Lonial	01/01/2024
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. Blood cancer journal	SA Scott, EM Marin, KT Maples, NS Joseph, CC Hofmeister, VA Gupta, MV Dhodapkar, JL Kaufman, S Lonial, AK Nooka	20/12/2023
Addressing the disparities: the approach to the African American patient with multiple myeloma. Blood cancer journal	M Bhutani, BJ Blue, C Cole, AZ Badros, SZ Usmani, AK Nooka, L Bernal-Mizrachi, J Mikhael	18/12/2023
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast. The oncologist	CS Lalonde, JM Switchenko, M Behera, MA Bilen, TK Owonikoko, JL Kaufman, AK Nooka, CM Lewis, E Hitron, H Collins, EC Judson, OB Alese, R Donald Harvey, JW Carlisle	11/12/2023
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial. Cancer	AK Nooka, AD Cohen, HC Lee, A Badros, A Suvannasankha, N Callander, AO Abdallah, S Trudel, A Chari, EN Libby, M Chaudhry, M Hultcrantz, KM Kortüm, R Popat, D Sborov, S Hakim, E Lewis, B Gorsh, B Bhushan, A McKeown, I Gupta, J Opalinska, PG Richardson, S Lonial	01/12/2023
Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. Clinical cancer research : an official journal of the American Association for Cancer Research	DJ Chung, N Shah, J Wu, B Logan, L Bisharat, N Callander, G Cheloni, K Anderson, T Chodon, B Dhakal, S Devine, P Somaiya Dutt, Y Efebera, N Geller, H Ghiasuddin, P Hematti, L Holmberg, A Howard, B Johnson, D Karagkouni, HM Lazarus, E Malek, P McCarthy, D McKenna, A Mendizabal, A Nooka, N Munshi, L O'Donnell, AP Rapoport, J Reese, J Rosenblatt, R Soiffer, D Stroopinsky, L Uhl, IS Vlachos, EK Waller, JW Young, MC Pasquini, D Avigan	01/12/2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity. Research square	A Moreno, K Manning, MI Azeem, AK Nooka, M Ellis, RJ Manalo, JM Switchenko, B Wali, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar, MS Suthar	21/09/2023
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction. JCO oncology practice	LF Sun, KT Maples, KH Hall, Y Liu, Y Cao, NS Joseph, CC Hofmeister, JL Kaufman, M Dhodapkar, AK Nooka, S Lonial, RD Harvey	01/09/2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity. bioRxiv : the preprint server for biology	A Moreno, K Manning, MI Azeem, AK Nooka, M Ellis, RJ Manalo, JM Switchenko, B Wali, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar, MS Suthar	22/08/2023
Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy. The Journal of clinical investigation	MH Robinson, NY Villa, DL Jaye, AK Nooka, A Duffy, SS McCachren, J Manalo, JM Switchenko, S Barnes, S Potdar, MI Azeem, AA Horvat, VC Parihar, J Gong, Y Liang, GH Smith, VA Gupta, LH Boise, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar	01/08/2023
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma. Cancer	TG Martin, MV Mateos, A Nooka, A Banerjee, R Kobos, L Pei, M Qi, R Verona, M Doyle, J Smit, W Sun, D Trancucci, C Uhlar, NWCJ van de Donk, C Rodriguez	01/07/2023
Cardiotoxicities of Cellular Therapies: A Practical Approach in a Sea of Uncertainty. JCO oncology practice	A Mandawat, AK Nooka	01/06/2023
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma. Journal of comparative effectiveness research	A Krishnan, AK Nooka, A Chari, AL Garfall, TG Martin, S Nair, X Lin, K Qi, A Londhe, L Pei, E Ammann, R Kobos, J Smit, T Parekh, A Marshall, M Slavcev, SZ Usmani	01/06/2023
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections. Blood cancer discovery	MI Azeem, AK Nooka, U Shanmugasundaram, N Cheedarla, S Potdar, RJ Manalo, A Moreno, JM Switchenko, S Cheedarla, DB Doxie, R Radzievski, ML Ellis, KE Manning, B Wali, RM Valanparambil, KT Maples, E Baymon, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, JD Roback, A Sette, R Ahmed, MS Suthar, AS Neish, MV Dhodapkar, KM Dhodapkar	01/03/2023
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience. Blood cancer journal	KT Maples, KH Hall, NS Joseph, CC Hofmeister, V Gupta, MV Dhodapkar, JL Kaufman, AK Nooka, S Lonial	20/02/2023
Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies. Cancer research communications	A Chang, A Akhtar, L Lai, VM Orellana-Noia, SL Linderman, AA McCook-Veal, JM Switchenko, M Saini, RM Valanparambil, KA Blum, PB Allen, MJ Lechowicz, JT Romancik, A Ayers, A Leal, CB O'Leary, MC Churnetski, K Baird, M Kives, J Wrammert, AK Nooka, JL Koff, MV Dhodapkar, MS Suthar, JB Cohen, R Ahmed	01/12/2022
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study. Future oncology (London, England)	AK Nooka, JL Kaufman, C Rodriguez, A Jakubowiak, Y Efebera, B Reeves, T Wildes, SA Holstein, LD Anderson, A Badros, L Shune, A Chari, H Pei, A Cortoos, S Patel, TS Lin, PG Richardson, P Voorhees	01/12/2022
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	RM Valanparambil, J Carlisle, SL Linderman, A Akthar, RL Millett, L Lai, A Chang, AA McCook-Veal, J Switchenko, TH Nasti, M Saini, A Wieland, KE Manning, M Ellis, KM Moore, SL Foster, K Floyd, ME Davis-Gardner, VV Edara, M Patel, C Steur, AK Nooka, F Green, MA Johns, F O'Brein, U Shanmugasundaram, VI Zarnitsyna, H Ahmed, LE Nyhoff, G Mantus, M Garett, S Edupuganti, M Behra, R Antia, J Wrammert, MS Suthar, MV Dhodapkar, S Ramalingam, R Ahmed	20/11/2022
EXABS-123-MM Additional Agents for RRMM - How Do/Will They Fit. Clinical lymphoma, myeloma & leukemia	AK Nooka, S Lonial	01/10/2022
Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma. Science advances	A Sharma, R Nair, A Achreja, A Mittal, P Gupta, K Balakrishnan, CL Edgar, O Animasahun, B Dwivedi, BG Barwick, VA Gupta, SM Matulis, M Bhasin, S Lonial, AK Nooka, AP Wiita, LH Boise, D Nagrath, M Shanmugam	30/09/2022
CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Clinical lymphoma, myeloma & leukemia	A Chang, L Lai, A Akhtar, S Linderman, V Orellana-Noia, M Saini, R Valanparambil, K Blum, P Allen, M Lechowicz, J Romancik, A Ayers, C O'Leary, M Churnetski, M Kives, A Nooka, J Koff, M Dhodapkar, M Suthar, J Cohen, R Ahmed	27/09/2022
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	AK Nooka, U Shanmugasundaram, N Cheedarla, H Verkerke, VV Edara, R Valanparambil, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, M Azeem, J Manalo, JM Switchenko, A Chang, SL Linderman, JD Roback, KM Dhodapkar, R Ahmed, MS Suthar, AS Neish, MV Dhodapkar	10/09/2022
Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	A Chang, A Akhtar, SL Linderman, L Lai, VM Orellana-Noia, R Valanparambil, H Ahmed, VI Zarnitsyna, AA McCook-Veal, JM Switchenko, JL Koff, KA Blum, AA Ayers, CB O'Leary, MC Churnetski, S Sulaiman, M Kives, P Sheng, CW Davis, AK Nooka, R Antia, MV Dhodapkar, MS Suthar, JB Cohen, R Ahmed	10/09/2022
β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma. Haematologica	R Nair, V Subramaniam, BG Barwick, VA Gupta, SM Matulis, S Lonial, LH Boise, AK Nooka, K Muthumalaiappan, M Shanmugam	01/09/2022
Venetoclax ex vivo functional profiling predicts improved progression-free survival. Blood cancer journal	VA Gupta, SM Matulis, BG Barwick, RD Bog, CW Shebelut, M Shanmugam, P Neri, NJ Bahlis, MV Dhodapkar, LT Heffner, CC Hofmeister, NS Joseph, S Lonial, JL Kaufman, DL Jaye, AK Nooka, LH Boise	04/08/2022
Carfilzomib 56 mg/m² twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison. Leukemia & lymphoma	K Weisel, AK Nooka, E Terpos, A Spencer, H Goldschmidt, F Dirnberger, L DeCosta, A Yusuf, S Kumar	01/08/2022
Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components. Transfusion	EL Snyder, AP Wheeler, M Refaai, CS Cohn, J Poisson, M Fontaine, M Sehl, AK Nooka, L Uhl, P Spinella, M Fenelus, D Liles, T Coyle, J Becker, M Jeng, EA Gehrie, BR Spencer, P Young, A Johnson, JJ O'Brien, GJ Schiller, JD Roback, E Malynn, R Jackups, ST Avecilla, JS Lin, K Liu, S Bentow, HL Peng, J Varrone, RJ Benjamin, LM Corash	01/07/2022
Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. Blood cancer journal	AK Nooka, JL Kaufman, C Rodriguez, A Jakubowiak, Y Efebera, B Reeves, T Wildes, SA Holstein, LD Anderson, A Badros, L Shune, A Chari, H Pei, A Cortoos, S Patel, JB Bartlett, J Vermeulen, TS Lin, PG Richardson, P Voorhees	13/04/2022
Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Pharmacotherapy	A Sivakumar, EB Bryson, KH Hall, KT Maples, S Goyal, NS Joseph, CC Hofmeister, JL Kaufman, S Lonial, AK Nooka, RD Harvey	01/03/2022
Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. Transplantation and cellular therapy	NS Joseph, VA Gupta, S Wyman, M Graiser, JL Kaufman, D Almaula, J Andrews, C Hofmeister, M Dhodapkar, LT Heffner, S Lonial, AK Nooka	01/02/2022
Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern. medRxiv : the preprint server for health sciences	R Valanparambil, J Carlisle, S Linderman, A Akthar, RL Millett, L Lai, A Chang, A McCook, J Switchenko, T Nasti, M Saini, AW Andreas Wieland, K Manning, M Ellis, K Moore, S Foster, K Floyd, M Davis-Gardner, V Viswanadh Edara, M Patel, C Steur, A Nooka, F Green, M Johns, F O Brein, U Shanmugasundaram, V Zarnitsyna, H Ahmed, L Nyhoff, G Mantus, M Garett, S Edupuganti, M Behra, R Antia, J Wrammert, M Suthar, M Dhodapkar, S Ramalingam, R Ahmed	23/01/2022
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. The Lancet. Oncology	SZ Usmani, H Quach, MV Mateos, O Landgren, X Leleu, D Siegel, K Weisel, M Gavriatopoulou, A Oriol, N Rabin, A Nooka, M Qi, M Beksac, A Jakubowiak, B Ding, A Zahlten-Kumeli, A Yusuf, M Dimopoulos	01/01/2022
"I took the road less traveled, and that has made all the difference": Making a case for high-dose therapy and autologous stem cell transplantation in elderly patients with newly diagnosed multiple myeloma. Cancer	AK Nooka, NS Joseph, S Lonial	15/11/2021
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer	S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, N Callander, D Sborov, A Suvannasankha, K Weisel, PM Voorhees, L Womersley, J Baron, T Piontek, E Lewis, J Opalinska, I Gupta, AD Cohen	15/11/2021
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. Blood cancer discovery	A Kaushal, AK Nooka, AR Carr, KE Pendleton, BG Barwick, J Manalo, SS McCachren, VA Gupta, NS Joseph, CC Hofmeister, JL Kaufman, LT Heffner, SM Ansell, LH Boise, S Lonial, KM Dhodapkar, MV Dhodapkar	01/11/2021
Selinexor for the treatment of patients with previously treated multiple myeloma. Expert review of hematology	CC Mo, S Jagannath, A Chari, AK Nooka, S Lonial, D Siegel, N Biran, C Gasparetto, NJ Bahlis, P Richardson	01/08/2021
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood	VA Gupta, BG Barwick, SM Matulis, R Shirasaki, DL Jaye, JJ Keats, B Oberlton, NS Joseph, CC Hofmeister, LT Heffner, MV Dhodapkar, AK Nooka, S Lonial, CS Mitsiades, JL Kaufman, LH Boise	01/07/2021
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood cancer journal	S Jagannath, Y Lin, H Goldschmidt, D Reece, A Nooka, A Senin, P Rodriguez-Otero, R Powles, K Matsue, N Shah, LD Anderson, M Streetly, K Wilson, HV Le, AS Swern, A Agarwal, DS Siegel	18/06/2021
Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research	BG Barwick, VA Gupta, SM Matulis, JC Patton, DR Powell, Y Gu, DL Jaye, KN Conneely, YC Lin, CC Hofmeister, AK Nooka, JJ Keats, S Lonial, PM Vertino, LH Boise	01/06/2021
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood cancer journal	S Lonial, AK Nooka, P Thulasi, AZ Badros, BH Jeng, NS Callander, HA Potter, D Sborov, BE Zaugg, R Popat, S Degli Esposti, J Byrne, J Opalinska, J Baron, T Piontek, I Gupta, R Dana, AV Farooq, K Colby, A Jakubowiak	26/05/2021
Maintenance Strategies for Myeloma: Is Bigger Always Better? Cancer journal (Sudbury, Mass.)	AK Nooka, NS Joseph	01/05/2021
Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. American journal of hematology	KT Maples, AK Nooka, V Gupta, NS Joseph, LT Heffner, C Hofmeister, M Dhodapkar, SM Matulis, S Lonial, LH Boise, JL Kaufman	01/03/2021
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. Blood cancer journal	Y Gu, BG Barwick, M Shanmugam, CC Hofmeister, J Kaufman, A Nooka, V Gupta, M Dhodapkar, LH Boise, S Lonial	14/12/2020
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clinical lymphoma, myeloma & leukemia	JL Kaufman, R Mina, JJ Shah, JP Laubach, AK Nooka, C Lewis, C Gleason, C Sharp, RD Harvey, LT Heffner, P Richardson, S Lonial, RZ Orlowski	01/12/2020
Primary refractory multiple myeloma: a real-world experience with 85 cases. Leukemia & lymphoma	A Jurczyszyn, A Waszczuk-Gajda, JJ Castillo, K Krawczyk, M Stork, L Pour, L Usnarska-Zubkiewicz, S Potoczek, I Hus, J Davila Valls, P Hari, S Chhabra, M Gentile, G Mikala, G Varga, CS Chim, M Fiala, R Vij, N Schutz, M Rodzaj, A Porowska, DH Vesole, A Druzd-Sitek, J Walewski, AK Nooka	01/12/2020
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmology and therapy	AV Farooq, S Degli Esposti, R Popat, P Thulasi, S Lonial, AK Nooka, A Jakubowiak, D Sborov, BE Zaugg, AZ Badros, BH Jeng, NS Callander, J Opalinska, J Baron, T Piontek, J Byrne, I Gupta, K Colby	01/12/2020
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmology and therapy	AV Farooq, S Degli Esposti, R Popat, P Thulasi, S Lonial, AK Nooka, A Jakubowiak, D Sborov, BE Zaugg, AZ Badros, BH Jeng, NS Callander, J Opalinska, J Baron, T Piontek, J Byrne, I Gupta, K Colby	01/12/2020
Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. JCO oncology practice	Y Yu, N Brown Wade, AE Hwang, AK Nooka, MA Fiala, A Mohrbacher, ES Peters, K Pawlish, C Bock, DJ Van Den Berg, KA Rand, D Stram, DV Conti, D Auclair, GA Colditz, J Mehta, CA Haiman, H Terebelo, N Janakiraman, S Singhal, B Chiu, R Vij, L Bernal-Mizrachi, JA Zonder, CA Huff, S Lonial, RZ Orlowski, W Cozen, S Ailawadhi	01/10/2020
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia	M Gavriatopoulou, A Chari, C Chen, N Bahlis, DT Vogl, A Jakubowiak, D Dingli, RF Cornell, CC Hofmeister, D Siegel, JG Berdeja, D Reece, D White, S Lentzsch, C Gasparetto, CA Huff, S Jagannath, R Baz, AK Nooka, J Richter, R Abonour, TL Parker, AJ Yee, P Moreau, S Lonial, S Tuchman, KC Weisel, M Mohty, S Choquet, TJ Unger, K Li, Y Chai, L Li, J Shah, S Shacham, MG Kauffman, MA Dimopoulos	01/09/2020
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. Journal of hematology & oncology	K Weisel, A Spencer, S Lentzsch, H Avet-Loiseau, TM Mark, I Spicka, T Masszi, B Lauri, MD Levin, A Bosi, V Hungria, M Cavo, JJ Lee, A Nooka, H Quach, M Munder, C Lee, W Barreto, P Corradini, CK Min, AA Chanan-Khan, N Horvath, M Capra, M Beksac, R Ovilla, JC Jo, HJ Shin, P Sonneveld, T Casneuf, N DeAngelis, H Amin, J Ukropec, R Kobos, MV Mateos	20/08/2020
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clinical lymphoma, myeloma & leukemia	MV Mateos, P Sonneveld, V Hungria, AK Nooka, JA Estell, W Barreto, P Corradini, CK Min, E Medvedova, K Weisel, C Chiu, JM Schecter, H Amin, X Qin, J Ukropec, R Kobos, A Spencer	01/08/2020
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. Journal for immunotherapy of cancer	N Shah, J Aiello, DE Avigan, JG Berdeja, IM Borrello, A Chari, AD Cohen, K Ganapathi, L Gray, D Green, A Krishnan, Y Lin, E Manasanch, NC Munshi, AK Nooka, AP Rapoport, EL Smith, R Vij, M Dhodapkar	01/07/2020
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI insight	N Bar, F Costa, R Das, A Duffy, M Samur, S McCachren, SN Gettinger, N Neparidze, TL Parker, JK Bailur, K Pendleton, R Bajpai, L Zhang, ML Xu, T Anderson, N Giuliani, A Nooka, HJ Cho, A Raval, M Shanmugam, KM Dhodapkar, MV Dhodapkar	18/06/2020
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	NS Joseph, JL Kaufman, MV Dhodapkar, CC Hofmeister, DK Almaula, LT Heffner, VA Gupta, LH Boise, S Lonial, AK Nooka	10/06/2020
Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor. Clinical lymphoma, myeloma & leukemia	J Mikhael, KR Noonan, B Faiman, C Gleason, AK Nooka, LJ Costa, S Jagannath, PG Richardson, D Siegel, A Chari, S Lentzch	01/06/2020
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. Blood cancer journal	R Mina, NS Joseph, F Gay, E Kastritis, MT Petrucci, JL Kaufman, V Montefusco, M Gavriatopoulou, F Patriarca, P Omedé, LH Boise, M Roussou, N Giuliani, S Oliva, M Offidani, A Belotti, DL Jaye, L De Paoli, E Terpos, S Lonial, M Boccadoro, AK Nooka, MA Dimopoulos	14/04/2020
Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nature communications	R Bajpai, A Sharma, A Achreja, CL Edgar, C Wei, AA Siddiqa, VA Gupta, SM Matulis, SK McBrayer, A Mittal, M Rupji, BG Barwick, S Lonial, AK Nooka, LH Boise, D Nagrath, M Shanmugam	06/03/2020
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. The Lancet. Oncology	S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, N Callander, N Lendvai, D Sborov, A Suvannasankha, K Weisel, L Karlin, E Libby, B Arnulf, T Facon, C Hulin, KM Kortüm, P Rodríguez-Otero, SZ Usmani, P Hari, R Baz, H Quach, P Moreau, PM Voorhees, I Gupta, A Hoos, E Zhi, J Baron, T Piontek, E Lewis, RC Jewell, EJ Dettman, R Popat, SD Esposti, J Opalinska, P Richardson, AD Cohen	01/02/2020
A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood advances	Z Du, N Weinhold, GC Song, KA Rand, DJ Van Den Berg, AE Hwang, X Sheng, V Hom, S Ailawadhi, AK Nooka, S Singhal, K Pawlish, ES Peters, C Bock, A Mohrbacher, A Stram, SI Berndt, WJ Blot, G Casey, VL Stevens, R Kittles, PJ Goodman, WR Diver, A Hennis, B Nemesure, EA Klein, BA Rybicki, JL Stanford, JS Witte, L Signorello, EM John, L Bernstein, AM Stroup, OW Stephens, M Zangari, F Van Rhee, A Olshan, W Zheng, JJ Hu, R Ziegler, SJ Nyante, SA Ingles, MF Press, JD Carpten, SJ Chanock, J Mehta, GA Colditz, J Wolf, TG Martin, M Tomasson, MA Fiala, H Terebelo, N Janakiraman, L Kolonel, KC Anderson, L Le Marchand, D Auclair, BC Chiu, E Ziv, D Stram, R Vij, L Bernal-Mizrachi, GJ Morgan, JA Zonder, CA Huff, S Lonial, RZ Orlowski, DV Conti, CA Haiman, W Cozen	14/01/2020
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. Haematologica	MV Mateos, A Spencer, AK Nooka, L Pour, K Weisel, M Cavo, JP Laubach, G Cook, S Iida, L Benboubker, SZ Usmani, SS Yoon, NJ Bahlis, C Chiu, J Ukropec, JM Schecter, X Qin, L O'Rourke, MA Dimopoulos	01/01/2020
Approaches to Treating Multiple Myeloma, Now and Moving Forward. JCO oncology practice	VA Gupta, NS Joseph, AK Nooka	01/01/2020
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood cancer journal	TM Schmidt, BG Barwick, N Joseph, LT Heffner, CC Hofmeister, L Bernal, MV Dhodapkar, VA Gupta, DL Jaye, J Wu, S Goyal, Z Chen, LH Boise, S Lonial, AK Nooka, JL Kaufman	25/11/2019
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. Cancer	AK Nooka, NS Joseph, JL Kaufman, LT Heffner, VA Gupta, C Gleason, LH Boise, S Lonial	01/09/2019
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. The New England journal of medicine	A Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, P Moreau, D Dingli, C Cole, S Lonial, M Dimopoulos, AK Stewart, J Richter, R Vij, S Tuchman, MS Raab, KC Weisel, M Delforge, RF Cornell, D Kaminetzky, JE Hoffman, LJ Costa, TL Parker, M Levy, M Schreder, N Meuleman, L Frenzel, M Mohty, S Choquet, G Schiller, RL Comenzo, M Engelhardt, T Illmer, P Vlummens, C Doyen, T Facon, L Karlin, A Perrot, K Podar, MG Kauffman, S Shacham, L Li, S Tang, C Picklesimer, JR Saint-Martin, M Crochiere, H Chang, S Parekh, Y Landesman, J Shah, PG Richardson, S Jagannath	22/08/2019
Daratumumab in multiple myeloma. Cancer	AK Nooka, JL Kaufman, CC Hofmeister, NS Joseph, TL Heffner, VA Gupta, HC Sullivan, AS Neish, MV Dhodapkar, S Lonial	15/07/2019
Registering a CD38 antibody upfront for multiple myeloma. Lancet (London, England)	CC Hofmeister, A Nooka, JL Kaufman, S Lonial	06/07/2019
Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. Leukemia	SM Matulis, VA Gupta, P Neri, NJ Bahlis, P Maciag, JD Leverson, LT Heffner, S Lonial, AK Nooka, JL Kaufman, LH Boise	01/05/2019
Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI insight	JK Bailur, SS McCachren, DB Doxie, M Shrestha, K Pendleton, AK Nooka, N Neparidze, TL Parker, N Bar, JL Kaufman, CC Hofmeister, LH Boise, S Lonial, ML Kemp, KM Dhodapkar, MV Dhodapkar	23/04/2019
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nature communications	BG Barwick, P Neri, NJ Bahlis, AK Nooka, MV Dhodapkar, DL Jaye, CC Hofmeister, JL Kaufman, VA Gupta, D Auclair, JJ Keats, S Lonial, PM Vertino, LH Boise	23/04/2019
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer	R Mina, NS Joseph, JL Kaufman, VA Gupta, LT Heffner, CC Hofmeister, LH Boise, MV Dhodapkar, C Gleason, AK Nooka, S Lonial	01/02/2019
Safety and survival outcomes for bloodless transplantation in patients with myeloma. Cancer	NS Joseph, JL Kaufman, LH Boise, K Valla, DK Almaula, CO Obidike, AA Langston, EK Waller, HJ Khoury, CR Flowers, M Graiser, LT Heffner, S Lonial, AK Nooka	15/01/2019
A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	KM Mullane, DJ Winston, A Nooka, MI Morris, P Stiff, MJ Dugan, H Holland, K Gregg, JA Adachi, SA Pergam, BD Alexander, ER Dubberke, N Broyde, SL Gorbach, PS Sears	07/01/2019
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. Blood cancer journal	JL Kaufman, R Mina, AJ Jakubowiak, TL Zimmerman, JJ Wolf, C Lewis, C Gleason, C Sharp, T Martin, LT Heffner, AK Nooka, RD Harvey, S Lonial	04/01/2019
Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma. Cancer journal (Sudbury, Mass.)	AK Nooka, S Lonial	01/01/2019
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nature communications	AE Tron, MA Belmonte, A Adam, BM Aquila, LH Boise, E Chiarparin, J Cidado, KJ Embrey, E Gangl, FD Gibbons, GP Gregory, D Hargreaves, JA Hendricks, JW Johannes, RW Johnstone, SL Kazmirski, JG Kettle, ML Lamb, SM Matulis, AK Nooka, MJ Packer, B Peng, PB Rawlins, DW Robbins, AG Schuller, N Su, W Yang, Q Ye, X Zheng, JP Secrist, EA Clark, DM Wilson, SE Fawell, AW Hird	17/12/2018
Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma. Future oncology (London, England)	S Chehab, EH Panjic, C Gleason, S Lonial, AK Nooka	01/12/2018
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica	A Spencer, S Lentzsch, K Weisel, H Avet-Loiseau, TM Mark, I Spicka, T Masszi, B Lauri, MD Levin, A Bosi, V Hungria, M Cavo, JJ Lee, AK Nooka, H Quach, C Lee, W Barreto, P Corradini, CK Min, EC Scott, AA Chanan-Khan, N Horvath, M Capra, M Beksac, R Ovilla, JC Jo, HJ Shin, P Sonneveld, D Soong, T Casneuf, C Chiu, H Amin, M Qi, P Thiyagarajah, AK Sasser, JM Schecter, MV Mateos	01/12/2018
Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. JAMA oncology	AK Nooka, ML Wang, AJ Yee, JL Kaufman, J Bae, D Peterkin, PG Richardson, NS Raje	01/12/2018
Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites. Cancer	S Chehab, C Zhang, EH Panjic, Z Chen, JL Kaufman, S Lonial, A Nooka, RD Harvey	15/11/2018
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Cancer	A Chari, S Lonial, TM Mark, AY Krishnan, KE Stockerl-Goldstein, SZ Usmani, A Londhe, D Etheredge, S Fleming, B Liu, J Ukropec, TS Lin, S Jagannath, AK Nooka	15/11/2018
Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma. Journal of oncology practice	A Chang, TH Nasti, MK Khan, S Parashar, JL Kaufman, LH Boise, S Lonial, R Ahmed, AK Nooka	01/09/2018
Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab. Journal of oncology practice	AK Nooka, C Gleason, MO Sargeant, M Walker, M Watson, EH Panjic, S Lonial	01/07/2018
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	DT Vogl, D Dingli, RF Cornell, CA Huff, S Jagannath, D Bhutani, J Zonder, R Baz, A Nooka, J Richter, C Cole, R Vij, A Jakubowiak, R Abonour, G Schiller, TL Parker, LJ Costa, D Kaminetzky, JE Hoffman, AJ Yee, A Chari, D Siegel, R Fonseca, S Van Wier, G Ahmann, I Lopez, M Kauffman, S Shacham, JR Saint-Martin, CD Picklesimer, C Choe-Juliak, AK Stewart	20/03/2018
14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors. Leukemia	Y Gu, K Xu, C Torre, M Samur, BG Barwick, M Rupji, J Arora, P Neri, J Kaufman, A Nooka, L Bernal-Mizrachi, P Vertino, SY Sun, J Chen, N Munshi, H Fu, J Kowalski, LH Boise, S Lonial	01/03/2018
CD86 regulates myeloma cell survival. Blood advances	CM Gavile, BG Barwick, S Newman, P Neri, AK Nooka, S Lonial, KP Lee, LH Boise	28/11/2017
Development of GLUT4-selective antagonists for multiple myeloma therapy. European journal of medicinal chemistry	C Wei, R Bajpai, H Sharma, M Heitmeier, AD Jain, SM Matulis, AK Nooka, RK Mishra, PW Hruz, GE Schiltz, M Shanmugam	20/10/2017
TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma. Blood advances	SP Shah, AK Nooka, S Lonial, LH Boise	26/09/2017
High-risk Multiple Myeloma: Definition and Management. Clinical lymphoma, myeloma & leukemia	NS Joseph, S Gentili, JL Kaufman, S Lonial, AK Nooka	01/07/2017
Daratumumab (anti-CD38) induces loss of CD38 on red blood cells. Blood	HC Sullivan, C Gerner-Smidt, AK Nooka, CM Arthur, L Thompson, A Mener, SR Patel, M Yee, RM Fasano, CD Josephson, RM Kaufman, JD Roback, S Lonial, SR Stowell	01/06/2017
Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study. Infection control and hospital epidemiology	NN Shah, W McClellan, CR Flowers, S Lonial, H Khoury, EK Waller, A Langston, AK Nooka	01/06/2017
Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. Blood	VA Gupta, SM Matulis, JE Conage-Pough, AK Nooka, JL Kaufman, S Lonial, LH Boise	06/04/2017
Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors. Bone marrow transplantation	Z DeFilipp, CB Rosand, DA Goldstein, VA Master, BC Carthon, WB Harris, O Kucuk, Z Al-Kadhimi, JB Cohen, CR Flowers, MJ Lechowicz, AK Nooka, JL Kaufman, AA Langston, Z Chen, J Arora, EK Waller	01/01/2017
A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology	KA Rand, C Song, E Dean, DJ Serie, K Curtin, X Sheng, D Hu, CA Huff, L Bernal-Mizrachi, MH Tomasson, S Ailawadhi, S Singhal, K Pawlish, ES Peters, CH Bock, A Stram, DJ Van Den Berg, CK Edlund, DV Conti, T Zimmerman, AE Hwang, S Huntsman, J Graff, A Nooka, Y Kong, SL Pregja, SI Berndt, WJ Blot, J Carpten, G Casey, L Chu, WR Diver, VL Stevens, MR Lieber, PJ Goodman, AJ Hennis, AW Hsing, J Mehta, RA Kittles, S Kolb, EA Klein, C Leske, AB Murphy, B Nemesure, C Neslund-Dudas, SS Strom, R Vij, BA Rybicki, JL Stanford, LB Signorello, JS Witte, CB Ambrosone, P Bhatti, EM John, L Bernstein, W Zheng, AF Olshan, JJ Hu, RG Ziegler, SJ Nyante, EV Bandera, BM Birmann, SA Ingles, MF Press, D Atanackovic, MJ Glenn, LA Cannon-Albright, B Jones, G Tricot, TG Martin, SK Kumar, JL Wolf, SL Deming Halverson, N Rothman, AR Brooks-Wilson, SV Rajkumar, LN Kolonel, SJ Chanock, SL Slager, RK Severson, N Janakiraman, HR Terebelo, EE Brown, AJ De Roos, AF Mohrbacher, GA Colditz, GG Giles, JJ Spinelli, BC Chiu, NC Munshi, KC Anderson, J Levy, JA Zonder, RZ Orlowski, S Lonial, NJ Camp, CM Vachon, E Ziv, DO Stram, DJ Hazelett, CA Haiman, W Cozen	01/12/2016
Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participation. Cancer	AK Nooka, M Behera, S Lonial, MD Dixon, SS Ramalingam, RD Pentz	15/10/2016
Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation. Oncotarget	SP Shah, AK Nooka, DL Jaye, NJ Bahlis, S Lonial, LH Boise	13/09/2016
Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leukemia & lymphoma	A Jurczyszyn, M Olszewska-Szopa, V Hungria, E Crusoe, T Pika, M Delforge, X Leleu, L Rasche, AK Nooka, A Druzd-Sitek, J Walewski, J Davila, J Caers, V Maisnar, M Gertz, M Gentile, D Fantl, G Mele, DH Vesole, AJ Yee, C Shustik, S Lentzsch, S Zweegman, A Gozzetti, AB Skotnicki, JJ Castillo	01/09/2016
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. The New England journal of medicine	A Palumbo, A Chanan-Khan, K Weisel, AK Nooka, T Masszi, M Beksac, I Spicka, V Hungria, M Munder, MV Mateos, TM Mark, M Qi, J Schecter, H Amin, X Qin, W Deraedt, T Ahmadi, A Spencer, P Sonneveld	25/08/2016
Is Maintenance Therapy for Everyone? Clinical lymphoma, myeloma & leukemia	AK Nooka, S Lonial	01/08/2016
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. Cancer biology & therapy	KG Ponder, SM Matulis, S Hitosugi, VA Gupta, C Sharp, F Burrows, AK Nooka, JL Kaufman, S Lonial, LH Boise	02/07/2016
Death by a thousand cuts: the slow demise of chemotherapy. Cancer	AK Nooka, S Lonial	01/07/2016
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. American journal of hematology	A Jurczyszyn, N Grzasko, A Gozzetti, J Czepiel, A Cerase, V Hungria, E Crusoe, AL Silva Dias, R Vij, MA Fiala, J Caers, L Rasche, AK Nooka, S Lonial, DH Vesole, S Philip, S Gangatharan, A Druzd-Sitek, J Walewski, A Corso, F Cocito, MC Vekemans, E Atilla, M Beksac, X Leleu, J Davila, A Badros, E Aneja, N Abildgaard, E Kastritis, D Fantl, N Schutz, T Pika, A Butrym, M Olszewska-Szopa, L Usnarska-Zubkiewicz, SZ Usmani, H Nahi, CS Chim, C Shustik, K Madry, S Lentzsch, A Swiderska, G Helbig, R Guzicka-Kazimierczak, N Lendvai, A Waage, KT Andersen, H Murakami, S Zweegman, JJ Castillo	01/06/2016
BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. Oncotarget	J Deng, D Park, M Wang, A Nooka, Q Deng, S Matulis, J Kaufman, S Lonial, LH Boise, J Galipeau, X Deng	10/05/2016
Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia	SM Matulis, VA Gupta, AK Nooka, HV Hollen, JL Kaufman, S Lonial, LH Boise	01/05/2016
Novel Combination Treatments in Multiple Myeloma. Oncology (Williston Park, N.Y.)	AK Nooka, S Lonial	01/05/2016
Myeloma Is Not a Single Disease. Journal of oncology practice	S Lonial, AK Nooka	01/04/2016
Meningeal Myelomatosis. Journal of oncology practice	Z DeFilipp, EA Sahovic, AK Nooka	01/02/2016
New Targets and New Agents in High-Risk Multiple Myeloma. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting	AK Nooka, S Lonial	01/01/2016
Referral Patterns and Clinical Outcomes for Transplant-Eligible Lymphoma and Myeloma Patients Evaluated at an Urban County Hospital. Journal of stem cell research & therapy	HD Yun, T Dossul, L Bernal-Mizrachi, J Switchenko, C Ndibe, A Ibraheem, MD Dixon, AA Langston, AK Nooka, CR Flowers, RD Pentz, EK Waller	01/01/2016
Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib. Oncology (Williston Park, N.Y.)	AK Nooka	01/12/2013
Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology	AO Kaseb, M Shama, IH Sahin, A Nooka, HM Hassabo, JN Vauthey, T Aloia, JL Abbruzzese, IM Subbiah, F Janku, S Curley, MM Hassan	01/01/2013
Clinical use of rituximab in patients with HIV related lymphoma and Multicentric Castleman's disease. Current drug delivery	E Reid, A Nooka, J Blackmon, MJ Lechowicz	01/01/2012
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research	AO Hoff, BB Toth, K Altundag, MM Johnson, CL Warneke, M Hu, A Nooka, G Sayegh, V Guarneri, K Desrouleaux, J Cui, A Adamus, RF Gagel, GN Hortobagyi	01/06/2008

Awards

Multiple Myeloma Research Foundation
International Myeloma Foundation (IMF) Special Research Grant, 2014
Multiple Myeloma Research Foundation (MMRF) Accelerator Award, 2013
Conquer Foundation ASCO Merit Award, Chicago, IL, 2011
Fellowship of American College of Physicians, 2011
AACR/ASCO Workshop: Methods in Clinical Cancer Research, Vail, CO, 2010
Frederick C. Whittier Excellence in Research Award, Canton Medical Education Foundation, OH, 2008
Rochfort Scholarship, Emory University, GA, 2008
Frederick C. Whittier Excellence in Research Award, Canton Medical Education Foundation, OH, 2007
American College of Physicians National Abstracts Competition, San Diego, CA, 2007
D. Jack Kilian Memorial Scholarship, UTSPH, Houston, TX, 2003

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.9	One star One star One star One star One half star	Provider showed concern
4.9	One star One star One star One star One half star	Provider explained things clearly
4.9	One star One star One star One star One half star	Provider discussed treatment options
4.9	One star One star One star One star One half star	Provider included you in decisions
4.9	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	27/04/2024	Dr Nooka was very nice, friendly and informative.He made sure I understood what the procedure and side effects were also.
One star One star One star One star One star	24/04/2024	I had an excellent experience with my health care provider. Very thorough in explaining procedures. I will most definitely recommend this care provider!
One star One star One star One star One star	23/03/2024	Dr. Nooka did a very good job of explaining our next steps for treatment. Very thorough doctor.
One star One star One star One star One star	06/03/2024	If you have to have cancer, this is the place to have it treated. Great place.
One star One star One star One star One star	01/03/2024	Dr Nooka seems excellent.
One star One star One star One star One star	27/02/2024	Dr Nooka has always showed a since of caring and interest in my health. He takes his time and explain my care to both myself and husband. My husband loves when he acknowledge him as a Veteran (thanking him for his service). He's professional and very thorough.
One star One star One star One star One star	27/02/2024	Dr Nooka took time to explain what I needed and why.
One star One star One star One star One star	27/02/2024	Dr. Nooka is very knowledgeable and carrying. In
One star One star One star One star One star	11/02/2024	Dr Nooka has been great throughout our whole experience- we have been very happy with his care and the rest of the Emory staff & professionals.
One star One star One star One star One star	05/02/2024	Great visit.
One star One star One star One star One star	21/01/2024	Very good experience.
One star One star One star One star One star	20/01/2024	My cancer is a keep an eye on situation so at the moment, thank goodness I don't need to go through treatment
One star One star One star One star One star	20/01/2024	Explained treatment very well
One star One star One star One star One star	15/01/2024	Dr. Nooka was very thorough and it was and it was a very good experience.
One star One star One star One star One star	12/01/2024	Loved his bedside manner. Didn't treat me like I didn't know what was going on . He answered all my questions and he listened to my concerns and discussed things with me. Very pleased with my visit
One star One star One star One star One star	08/01/2024	The doctor was very nice and professional. He explained everything clearly so I could understand better. I really appreciated the time he took to explain things to me and my family.
One star One star One star One star Empty star	04/12/2023	Appreciate the opportunity to not only ask multiple questions but also the responses provided until it is clear I understand the lab results.
One star One star One star One star One star	02/12/2023	Dr. Nooka is fantastic.
One star One star One star One star One star	02/12/2023	Dr Nooka and the staff supporting him are excellent!! Might I have a wait a bit to see him. Yep but he is worth waiting for. :-)
One star One star One star One star One star	25/11/2023	Awesome, explained procedures, made me comfortable, rather than nervous , answered all my questions, even when I asked the same question twice, patient and answered every question, wrote example on board.
One star One star One star One star One star	21/11/2023	Yes everything was great and Dr. Nooka is a wonderful doctor and anyone who is treated by him is a lucky person.
One star One star One star One star One star	21/11/2023	Dr Nooka does this in an excellent manner. He explains well and is considerate.
One star One star One star One star One star	11/11/2023	Love Dr.Nooka!!
One star One star One star One star One star	10/11/2023	The provider was very courteous helpful and informative.
One star One star One star One star One star	09/11/2023	Doctor Nooka handled the visit very professionally all our concerns and questions were handled. Doubtful there is a better more professional Doctor at Emory so of course the visit went perfectly.
One star One star One star One star One star	06/11/2023	Doctor and nurse explained what to expect and answered our questions.
One star One star One star One star One star	04/11/2023	Love Dr. Nooka and staff. Love Emory
One star One star One star One star One star	31/10/2023	Dr. Nooka always shows caring attitude.
One star One star One star One star One star	21/10/2023	Dr. Nooka was exceptional. Not only is he knowledgeable, he is reassuring, comforting, and has great bedside manner. He explained everything thoroughly and patiently answered my questions. I'm so happy we found him!
One star One star One star One star One star	19/10/2023	Trust is good
One star One star One star One star One star	09/10/2023	Dr Nokia was amazingly informative, patient and empathetic. I was very unmoressed with him and have every confidence I will be in the best hands with him and his staff.
One star One star One star One star One star	06/10/2023	Dr. Nooka has consistently shown genuine concern for my treatment and well-being.
One star One star One star One star One star	22/09/2023	Very professional healthcare services provided. Thanks
One star One star One star One star One star	16/09/2023	Very helpful and informative
One star One star One star One star One star	18/08/2023	Excellent Doctor
One star One star One star One star One star	05/08/2023	Dr Nooka is the top of the line very best. A life savor
One star One star One star One star One star	01/08/2023	Proactive
One star One star One star One star One star	29/07/2023	We have never had a bad experience at Emory. The entire staff is so helpful and caring.
One star One star One star One star One star	18/07/2023	Dr Nooka is absolutely incredible and so much so that I often forget that I am speaking with my health care provider and not a dear friend or relative. He always takes the time to answer my questions in a way that I can understand.
One star One star One star One star One star	03/07/2023	Dr.Nooka as always was clear and precise with his explanations of scheduling, and treatments. Anyone who has the opportunity to have Dr. Nooka as a Care Provider is truly blessed.
One star One star One star One star One star	28/06/2023	I have been with Dr Nooka sine he first became a member of the medical staff. His guidance and medical knowledge is top notch !
One star One star One star One star One star	27/06/2023	Dr Nooka is an awesome doctor
One star One star One star One star One star	27/06/2023	Totally professional.Very confident that Dr.Nooka has my best interest at heart.
One star One star One star One star One star	20/06/2023	All care providers made me feel comfortable and answered all my questions
One star One star One star One star One star	27/05/2023	Dr Nooka . Soooo good!!!!
One star One star One star One star One star	23/05/2023	Dr. Nooka is a wonderful Dr. And has helped me so much. He explained everything to me and I could understand the charts he showed me. I would recommend him to everyone. I am grateful for Dr. Nooka and Emory.
One star One star One star One star One star	23/05/2023	Dr Nooka is exceptionally patient and willing to discussItems.
One star One star One star One star One star	20/05/2023	Dr. Nooka answered all my questions in detail
One star One star One star One star One star	18/05/2023	Included my wife in the discussion, answering all of her questions
One star One star One star One star One star	18/05/2023	Dr. Nooka is an excellent doctor!! He always answers all of our questions and concerns!!
One star One star One star One star One star	16/05/2023	Dr. Nooka is a fantastic clinical doctor.
One star One star One star One star One star	10/05/2023	I'm a retired surgeon.Dr Nooka was very helpful in explaining my diagnosis and treatment Excellent care
One star One star One star One star One star	08/05/2023	Very good meeting with the doctor
One star One star One star One star One star	11/04/2023	Dr Nooka is the best! I have been under his care for almost,11 years.we have been through a lot in that period I always know he will do what ever is needed for me hopefully we will work together for my continued success
One star One star One star One star One star	27/03/2023	Patient and informative
One star One star One star One star One star	21/03/2023	Satisfied
One star One star One star One star One star	01/03/2023	I find Emory providers always to be excellent.
One star One star One star One star One star	21/02/2023	We came because we weren't getting good answers for treatment options from another place. Were very pleased with the options we were given and the explanation of them.
One star One star One star One star One star	20/02/2023	I felt like everyone took their time to make sure I understood everything thoroughly before they went on and that I felt comfortable with everything.
One star One star One star One star One star	18/02/2023	Dr was excellent in explaining my problem and made me understand
One star One star One star One star One star	04/02/2023	Dr. Nooka is the best! All the other PAs I have seen are ALWAYS top notch and never any negative issues with them.
One star One star One star One star One star	04/02/2023	Good
One star One star One star One star One star	17/01/2023	Good interchange of information.
One star One star One star One star One half star	17/11/2022	Went very well
One star One star One star One star One star	24/09/2022	Excellent discussion e DR Ver helpful input on my treatment
One star One star One star One star One star	15/09/2022	All the helpers were very kind during their duties
One star One star One star One star One star	23/08/2022	I don't usually rate anyone or any business with perfect scores as I have always felt that they could do better and that no one is perfect. Dr. Nooka is an exception in that regard as he is intelligent, caring, and patient as I process everything that he shares with me. Cancer is complicated and can cause high anxiety in most patients but he is a calming voice on the other end of the phone or camera. Even if he doesn't have all of the answers I always walk away knowing that he has my best interest at heart and that he will do the very that he can to care for me as his patient. His bedside manner is rare!
One star One star One star One star One star	20/08/2022	Dr. Nooka is always good about taking the time to answer my questions and to explain things.
One star One star One star One star One star	09/08/2022	Dr. Nooka is the "Best Physician" in his field and I'm so grateful that I was recommended to him. He displays love, concern, patience and a forward thinking approach to ensure that his patients receive the utmost care. He always make sure his patients understand everything he is saying during any session. I would recommend him to my family and friends as the best doctor to receive excellent service in his profession at Emory University Hospital.
One star One star One star One star Empty star	09/08/2022	The experience definitely works better when questions are written prior to the zoom meeting.
One star One star One star One star One star	30/07/2022	The medical world moves soFast with each visit Dr. Nooka keeps me abreast of the new treatments of myeloma
One star One star One star One star One star	30/07/2022	This was the first visit with Dr. Nooka and was very impressed, I have had concerns following Dr. Hefner retirement but no longer.
One star One star One star One star One star	26/07/2022	Dr. Nooka is a fantastic doctor and I am greatful for his care.
One star One star One star One star One star	31/05/2022	Everyone was informative and very nice. Superlatives all around.
One star One star One star One star One star	19/05/2022	He was very clear with his description and knowledge of what I was there for. I was satisfied with his answers to my questions.